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Background: Intravenous (IV) iron is widely used to treat anemia in chronic kidney
disease patients. Previously, iron formulations were shown to induce immune
activation in-vitro. The current study aimed to investigate the effect of IV iron on
complement activation in-vivo, and whether this subsequently induces inflammation
and/or oxidative stress.
Methods: Two distinct patient groups were included: 51 non-dialysis and 32 dialysis
patients. The non-dialysis group received iron sucrose or ferric carboxymaltose, based
on physicians’ choice. Plasma samples were collected prior to and 1 h after completion
of IV iron infusion. The dialysis group received iron sucrose exclusively. Plasma samples
were collected at the start and end of two consecutive hemodialysis sessions, one with
and one without IV iron. Finally, plasma levels of MBL, C1q, properdin, factor D, sC5b-9,
MPO, PTX3 were assessed by ELISA.
Results: In the non-dialysis group, sC5b-9 levels significantly increased after IV
iron by 32%, while levels of factor D and MBL significantly dropped. Subgroup
analysis demonstrated that iron sucrose induced complement activation whereas ferric
carboxymaltose did not. In the dialysis group, levels of sC5b-9 significantly increased
by 46% during the dialysis session with IV iron, while factor D levels significantly fell.
Furthermore, the relative decrease in factor D by IV iron correlated significantly with the
relative increase in sC5b-9 by IV iron. MPO levels rose significantly during the dialysis
session with IV iron, but not in the session without iron. Moreover, the relative increase
in MPO and sC5b-9 by IV iron correlated significantly. PTX3 levels were not affected by
IV iron.
Conclusions: Iron sucrose but not ferric carboxymaltose, results in complement
activation possibly via the lectin and alternative pathway partially mediating oxidative
stress but not inflammation.
Keywords: kidney, complement, hemodialysis, iron, anemia and kidney disease
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INTRODUCTION
Intravenous (IV) iron drugs are a mainstay in the management
of anemia (1). A growing number of chronic kidney disease
(CKD) patients receive IV iron (1, 2). In the past, safety
concerns existed, since IV iron has been linked to iron overload,
increased oxidative stress, cardiovascular risk, infection risk,
and hypersensitivity reactions (1, 3). Recently, a multicenter
open-label clinical trial with over 2,000 hemodialysis (HD)
patients demonstrated that a high-dose IV iron sucrose regimen
administered pro-actively resulted in lower cardiovascular events
(29 vs. 32%) when compared to a low-dose IV iron sucrose
regimen, while no difference in infection and mortality was seen
(4). However, some questions persist about the long-term safety
of IV iron, the comparison of different iron formulations and
the clinical outcome in non-dialysis patients. Therefore, a better
understanding of the IV iron (side) effects remains a relevant
subject of research.
Previously, hypersensitivity reactions induced by IV iron
have been proposed to arise from complement activation-
related pseudo-allergy (CARPA) (5). Complement activation
can be initiated via three different pathways: the classical
pathway (CP), the lectin pathway (LP), and the alternative
pathway (AP). All the pathways converge at the level of C3
and ultimately results in generation of C5b-9, the membrane
attack complex (MAC) (6). Hypersensitivity reactions are
extremely rare, making it difficult to establish a cohort large
enough to investigate the CARPA hypothesis (7). Nevertheless,
the concept of complement activation by IV iron warrants
further investigation. A few studies have previously shown
the ability of IV iron formulations to activate complement
in-vitro (8, 9). For instance, low-molecular weight iron dextran,
ferric gluconate, ferric carboxymaltose, and iron sucrose were
all shown to activate complement. However, the paradoxical
results found in these studies, emphasize the need for
further research.
The current study aimed to investigate the effect of IV iron
on complement activation in-vivo. In addition, we explored if
a potential IV iron induced complement activation could lead
to oxidative stress and inflammation. Therefore, complement
activation was assessed through the measurement of sC5b-9
levels and components of different pathways, namely C1q from
the CP, MBL from the LP and factor D and properdin from the
AP. Also, inflammation and oxidative stress were studied through
the measurement of myeloperoxidase (MPO) and pentraxin-3
(PTX-3). All these measurements were performed in distinct
groups receiving IV iron treatment.
Abbreviations: AP, Alternative pathway; CARPA, Complement activation
related pseudoallergy; CKD, Chronic kidney disease; ND-CKD, Non-dialysis
chronic kidney disease; CP, Classical pathway; CRP, C reactive protein; EDTA,
Ethylenediaminetetraacetic acid; HD, Hemodialysis; IL-6, Interleukin-6; IV,
Intravenous; LP, Lectin pathway; MAC, Membrane attack complex; MBL,
Mannose-binding lectin; MPO, Myeloperoxidase; PTX3, Pentraxin-3; sC5b-9,
soluble membrane attack complex; SEM, Standard error of the mean; TNF-α,
Tumor necrosis factor alpha.
MATERIALS AND METHODS
Study Design and Population
Patients were recruited from the day clinic and the dialysis unit of
Hospital de Braga, Braga, Portugal. The first group included non-
dialysis patients (CKD and non-CKD), receiving iron sucrose
(Venofer R©, Vifor Pharma) or ferric carboxymaltose (Ferinject R©,
Vifor Pharma) and the second group consisted of dialysis patients
receiving only iron sucrose. Adult patients (≥18 years) receiving
IV iron and who gave informed consent were eligible for the
study. Exclusion criteria were administration of iron in the
previous 3 months for the first group whereas signs of active
inflammation was exclusion criteria for both groups.
In the non-dialysis group, the drug type and the dose of IV
iron was based on the decision of the treating physician according
to local clinical guidelines and protocols. Iron was infused
with a slow infusion rate and complete drug administration
occurred in 30min for 100mg of iron sucrose and 500mg
of ferric carboxymaltose, whereas higher doses of both drugs
were infused in 1 h. Plasma EDTA samples were collected
prior to and 1 h after completion of the iron infusion. During
this period, patients were observed for allergic symptoms and
signs, including itching, arthralgias, hypotension, tachycardia,
respiratory symptoms, thoracic pain, edema, and/or rash.
In the dialysis group, patients received online-
hemodiafiltration three times per week for 4 h using high
flux polysulfone dialyzers (Fx80, Helixone, Fresenius Medical
Care, St. Wendel, Germany). Two patients were dialyzed with
cellulose triacetate filters (CT190G, Baxter, McGaw Park, IL,
USA). Patients received iron sucrose starting 3 h after the start
of the dialysis session through a slow IV injection over 2min via
the venous limb of the circuit. The treating physician decided the
dose of the IV iron formulation. Samples were collected during
two consecutive sessions, one with IV iron administration and
one without. During each dialysis session, plasma EDTA samples
were collected prior to dialysis (pre-dialysis) and after 4 h, at the
end of the session (post-dialysis).
All blood samples were centrifuged within 30min of collection
at 3500 rpm for 15min. Next, the samples were stored in
aliquots at −80◦C until the measurement of the different
laboratory parameters. Prior to the assay, samples were thawed
and re-centrifuged.
Laboratory Procedures
Levels of sC5b-9 levels,C1q, MBL, factor D, and properdin were
quantified in plasma EDTA samples by in-house sandwich ELISA
as previously described (8, 10). In brief, plates were coated
overnight at 4◦C with the respective antibody in coating buffer
(100mM Na2CO3/NaHCO3, pH 9.6). After coating, plates were
blocked using 1% BSA/PBS. Next, plasma samples were diluted
into the appropriate buffer solution and incubated in the coated
wells. The protein of choice was then detected using the DIG- or
biotin-conjugated coating antibody followed by detection with
streptavidin-poly-horseradish peroxidase or HRP-conjugated
sheep anti-Dig Antibodies (Fab fragments, Roche, Mannheim,
Germany). After each step the plate was washed in PBS Tween-
20 (0.05%) and all incubation steps were done for 1 h at
Frontiers in Immunology | www.frontiersin.org 2 August 2019 | Volume 10 | Article 1885
Faria et al. IV Iron Induces Complement Activation
37◦C. For visualization 3,3′,5,5′′-Tetramethylbenzidine (TMB) or
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS)
was added and the optical density was measured at 450 or
415 nm, respectively. For the C1q and properdin ELISA, in
house antibodies were used. For the other ELISAs anti-MBL 3e7
antibody (Hycult, Uden, The Netherlands), anti-factor D 18241
antibody (R&D systems, Wiesbaden-Norderstedt, Germany) or
anti-C5b-9 AE11 antibody (DAKO, Copenhagen, Denmark)
was used. The capture antibody for the sC5b-9 ELISA was
different from the coating antibody and instead a goat anti-
human C5 antibody was used (Sigma–Aldrich, St. Louis, MO,
USA). MPO and PTX3 were measured using commercial ELISA
kits according to themanufacturers’ instructions (Hycult Biotech,
Uden, The Netherlands).
Statistics
Statistical analysis was performed using IBM SPSS 23.0 (IBM
Corporation, Chicago, IL, USA). Laboratory measurements
are shown as mean ± standard error of the mean (SEM).
Comparisons between samples were made by paired sample
t-test. Correlations were assessed using Pearson correlation
coefficient (r). P-values <0.05 were considered to be statistically
significant. The ratios used for the analyses were calculated per
patient by dividing the pre-dialysis level by the post-dialysis level
in both sessions. Subsequently the relative increase was calculated
dividing the ratio of the session with iron, by the session without.
Ethics
This study was performed in accordance to the Declaration
of Helsinki and was approved by the Medical Ethical
Committee from Hospital Braga. All participants signed
informed written consent.
RESULTS
Intravenous Infusion of Iron Sucrose Leads
to Complement Activation in Non-dialysis
Patients
The effect of IV iron on the complement system was first assessed
in the non-dialysis group. This consisted of 51 patients with a
median age of 64 years of which 63% were female (Table 1).
Fifteen had non-dialysis CKD (ND-CKD) and 36 were non-CKD
patients with anemia due to gastrointestinal or gynecological
origin. Seventeen patients received ferric carboxymaltose at doses
of 500mg (n = 3) or 1,000mg (n = 14), while 34 received iron
sucrose at doses of 100mg (n = 13), 200mg (n = 20) or 300mg
(n= 1). No hypersensitivity reactions were observed.
Overall, IV iron administration resulted in significant higher
levels of sC5b-9 compared to baseline (P = 0.007; Figure 1A).
The mean baseline values were 65.9 ± 17.1 ng/mL and rose
to 87.3 ± 11.3 ng/mL after infusion, representing an average
increase of 32% in sC5b-9 levels by IV iron. Nevertheless, the
magnitude of the changes in levels of sC5b-9 by iron infusion
varied, with 84% of patients showing complement activation by
IV iron (Figure 1B). Next, we performed subgroup analyses of
ND-CKD vs. non-CKD. In the ND-CKD group, levels of sC5b-
9 were significantly increased by iron treatment (P = 0.007,





Age, years 64.3 ± 19.8 69.4 ± 15.7
Female gender, n (%) 32 (63) 9 (28)
Weight, kg 69.3 ± 13.6 71.7 ± 10.9
BMI, kg/m2 28.5 ± 4.9 26.5 ± 4.2
Diabetes, n (%) 13 (25) 17 (53)
Anemia Etiology, n (%)
Gastro-intestinal 27 (53) 0
Gynecological 9 (18) 0
Kidney Disease 15 (29) 32 (100)
Mixed* 8 (16) 4 (12)
Stages of CKD (KDIGO), n (%)
III 6 (40) 0
IV 6 (40) 0
V 3 (20) 32 (100)
Hemoglobin, g/dL 9.7 ± 2.1 11.4 ± 1.2
Serum ferritin concentration, ng/mL 48.1 ± 87.4 357 ± 188
Transferrin saturation, % 10.8 ± 8.3 30.9 ± 19.4
Type of IV Iron, n (%)
Iron Sucrose 34 (67) 32 (100)
20mg 0 4 (12)
50mg 0 15 (47)
100mg 13 (25) 13 (41)
200mg 20 (39) 0
300mg 1 (2) 0
Ferric Carboximaltose 17 (33) 0
500mg 3 (6)
1,000mg 14 (27)
Other anemia treatments, n (%)
Oral Iron supplementation 18 (35) 0
Erythropoiesis stimulating agents 6 (12) 30 (94)
BMI, body mass index; CKD, Chronic Kidney Disease; KDIGO, Kidney Disease Improving
Global Outcomes; IV, intravenous.
All patients were Caucasians and data is expressed as means ± standard error of the
mean or absolute numbers (percentage).
*Involving more than one anemia etiology.
Figure 1C), whereas in the non-CKD there was a trend for
higher levels of sC5b-9 by IV iron (P = 0.05). Furthermore,
infusion of iron sucrose was compared to ferric carboxymaltose.
IV infusion with iron sucrose resulted in a significant rise in
sC5b-9 levels (P < 0.001; Figure 1D). Baseline levels of sC5b-
9 were 53.6 ± 6.6 ng/mL and after IV iron increased to 89.7
± 7.1 ng/mL, showing an increase of 67%. In contrast, sC5b-9
levels were not significantly altered by iron infusion with ferric
carboxymaltose (P = 0.76; Figure 1D). Of note, baseline levels
were not statistically different between patients receiving iron
sucrose compared to ferric carboxymaltose.
To explore the effect of IV iron on complement components,
C1q, properdin, factor D, andMBL were measured. Iron infusion
was associated with a significant fall in the levels of factor D
(P = 0.007; Figure 2A) and MBL compared to baseline (P =
0.006; Figure 2B), whereas properdin and C1q levels were not
significantly altered after IV iron administration (Table 2).
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FIGURE 1 | The effect of IV iron on complement activation, as assessed by soluble C5b-9 in non-dialysis patients. (A) The plasma levels of soluble C5b-9 (sC5b-9)
were determined in 51 patients prior to and 1 h after completion of iron infusion. (B) The ratio of sC5b-9 was calculated per patient by dividing the pre-iron level by the
post-iron level. Horizontal lines indicate the mean. A post/pre-ratio higher than 1, indicates an increase in concentration by iron. Subgroup analysis of plasma sC5b-9
levels in (C) chronic kidney disease (CKD) patients (n = 15) vs. non-CKD patients (n = 36). (D) In patients receiving ferric carboxymaltose (n = 17) vs. iron sucrose
(n = 34). Data are presented as mean and SEM (A,C,D). Paired sample t-test was used to compare values before and after iron infusion. P-values <0.05 were
considered to be statistically significant (**P < 0.01, ***P < 0.001).
FIGURE 2 | Consumption of mannose-binding lectin and Factor D following intravenous iron in non-dialysis patients. In 51 non-dialysis patients plasma levels of (A)
factor D and (B) mannose-binding lectin (MBL) were determined prior to and 1 h after completion of iron infusion. Data are presented as mean and SEM. Paired
sample t-test was used to compare values before and after iron infusion. P-values <0.05 were considered to be statistically significant (**P < 0.01).
Iron Infusion Has No Effect on Oxidative
Stress or Inflammation in Non-dialysis
Patients
Subsequently, we determined the effect of IV iron on oxidative
stress and inflammation by measuring levels of MPO and
PTX3, respectively. Iron infusion resulted in a 33% increase of
MPO levels, yet this rise was not statistically significant (P =
0.17; Figure 3A). PTX3 levels were unaffected by iron infusion,
showing similar levels before and after iron infusion (P = 0.68;
Figure 3B). In subgroup analysis, infusion of iron sucrose led
to a non-significantly increase of MPO levels by 41% (P =
0.18), while PTX3 levels were not affected. The use of ferric
carboxymaltose did not significantly affect MPO or PTX3 levels
(data now shown).
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Intravenous Infusion of Iron Sucrose Leads
to Complement Activation in Hemodialysis
Patients
Next, we analyzed the effect of iron sucrose on complement
activation in 32 dialysis patients, at doses of 100mg (n =
TABLE 2 | The effect of intravenous iron on C1q and properin in non-dialysis
patients and the correlation with soluble C5b-9.
sC5b-9
Pre-iron Post-iron P* R P#
C1q (µg/mL) 69.4 ± 4.5 64.9 ± 4.4 0.20 0.03 0.8
Properdin (µg/mL) 10.1 ± 0.8 8.8 ± 0.5 0.06 −0.14 0.3
Values are expressed as mean ± standard error of the mean. P* indicates P-values
for difference between samples pre and post-iron tested by paired t-test. R indicates
Pearson correlation coefficient between Post-iron/Pre-iron ratio between the complement
component and sC5b-9, and the corresponding P-value is shown by P#.
13), 50mg (n = 15), and 20mg (n = 4). The mean age was
69 years and 72% were male (Table 1). During the study, no
hypersensitivity reactions were observed in the dialysis patients.
In the dialysis session without IV iron, sC5b-9 levels were
not significantly increased after dialysis (P = 0.27; Figure 4A).
However, IV iron during dialysis resulted in a significant rise
of levels of sC5b-9 compared to baseline (P = 0.001) as well as
compared to the end of the dialysis session without iron (P =
0.002; Figure 4A). IV iron resulted in an increase of 46% in sC5b-
9 levels, compared to a 14% increase in the dialysis without IV
iron. Of note, the magnitude of the change in sC5b-9 levels by
iron infusion varied, with 60% of the dialysis patients showing
complement activation by IV iron (Figure 4B).
Once again, levels of C1q, properdin, factor D, and MBL
were assessed to study the effect of IV iron on complement
components (Table 3). Factor D levels did not significantly
change during standard hemodialysis (P = 0.39, Figure 5A), but
were significantly reduced after the dialysis session with IV iron
infusion (P = 0.002; Figure 5A). Moreover, the relative decrease
FIGURE 3 | Pentraxin-3 and myeloperoxidase are not altered by intravenous iron in non-dialysis patients. In 51 non-dialysis patients, plasma levels of (A)
myloperoxidase (MPO) and (B) pentraxin-3 (PTX3) were determined prior to and 1 h after completion of iron infusion. Data are presented as mean and SEM. Paired
sample t-test was used to compare values before and after iron infusion. P-values <0.05 were considered to be statistically significant.
FIGURE 4 | Iron sucrose results in complement activation in dialysis patients. (A) Plasma levels of soluble C5b-9 (sC5b-9) were determined in 32 hemodialysis
patients during two consecutive dialysis sessions, one with intravenous iron (Iron), and one without (No iron). During each dialysis session, sC5b-9 levels were
determined at baseline and after 4 h. Data are presented as mean and SEM. (B) The relative change in sC5b-9 was calculated per patient by dividing the pre-dialysis
level by the post-dialysis level in both sessions and subsequently diving the session with iron, by the session without. Horizontal lines indicate the mean. A
post/pre-ratio higher than one, indicates an increase in concentration of sC5b-9 by iron sucrose. The paired sample t-test was used to compare values before and
after iron infusion. P-values <0.05 were considered to be statistically significant (**P < 0.01).
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TABLE 3 | The effect of intravenous iron on complement levels in dialysis patients and the correlation with soluble C5b-9.
No iron Iron sC5b-9
Pre-HD Post-HD P* Pre-HD Post-HD P% R P
C1q (µg/mL) 39.7 ± 9.8 43.2 ± 10.0 0.6 42.06 ± 10.3 40.8 ± 9.3 0.8 −0.13 0.4
MBL(ng/mL) 862 ± 145 1,087 ± 229 0.1 1,660 ± 688 1,518 ± 570 0.8 0.03 0.9
Properdin (µg/mL) 9.1 ± 1.2 9.6 ± 6.3 0.8 11.4 ± 1.4 12.0 ± 1.8 0.6 −0.30 0.4
Values are expressed as mean ± standard error of the mean. P* indicate P-values for the difference between samples pre and post-HD in the HD session without iron tested by paired
t-test. P% indicate P-values for the difference between samples pre and post-HD in the HD session with iron tested by paired t-test. In the last column, R indicates Pearson correlation
coefficient between Post-HD/Pre-HD ratio between the sessions of the complement component compared with the Post-HD/Pre-HD ratio between the sessions of sC5b-9.
of factor D by IV iron correlated with the relative increase of
sC5b-9 by IV iron (r = 0.49, P = 0.004; Figure 5B), suggesting
that consumption of factor D is linked to complement activation.
Administration of IV iron during dialysis did not significantly
affect MBL, C1q or properdin levels (Table 3).
Intravenous Iron Sucrose Leads to Higher
MPO Levels in Hemodialysis Patients, and
Is Correlated With Complement Activation
The dialysis session without IV iron infusion showed no
significant changes in MPO levels (P = 0.36; Figure 6A), while,
the dialysis session with IV iron resulted in a significant rise in
MPO levels (P = 0.02; Figure 6A). Levels of MPO showed an
increase of 47% compared to baseline. Moreover, the relative
increase of MPO levels by IV iron correlated significantly with
the relative increase in C5b-9 levels by IV iron (r= 0.42, P= 0.02;
Figure 6B). Levels of PTX3 were already significantly increased
by dialysis itself (P = 0.002; Figure 6C) and administration of IV
iron did not result in a further increase.
DISCUSSION
The current study demonstrates, for the first time, that
administration of iron sucrose, but not ferric carboxymaltose,
results in complement activation in-vivo. Iron sucrose induced
complement activation in both non-dialysis and dialysis patients.
However, while in the majority of patients iron sucrose led to
complement activation, the magnitude of the response to IV iron
varied considerably among the patients. Complement activation
induced by iron sucrose is possibly mediated via the AP, since
factor D consumption by IV iron correlated with increased
levels of sC5b-9. However, involvement of the LP cannot be
excluded since iron infusion in the non-dialysis patients resulted
in lower MBL levels. Finally, iron sucrose significantly increased
MPO levels during dialysis and the relative increase of MPO
correlated with complement activation. This finding suggests that
complement activation induced by IV-iron is linked to neutrophil
activation resulting in oxidative stress.
Previously, our group tested the in-vitro ability of different
iron formulations to activate the complement system (8). Based
on the in-vitro studies, complement activation by iron sucrose
was thought to occur via LP activation. The current findings
implicate AP and possibly LP activation by iron sucrose. We
found a significant reduction of factor D by IV iron and also a
trend for lower properdin in the non-dialysis group, implying
AP involvement. The significant decrease in MBL levels in the
non-dialysis group could suggest a role for LP activation by iron
sucrose. Recent studies indicate that activation of the AP can
be mediated via the LP, more specifically initiation of the MBL-
MASP complex can result in the conversion of pro-factor D in
factor D by MASP-3 (11). The mechanisms behind complement
activation induced by iron drugs are still unclear. A crucial
difference between the iron formulations are the carbohydrate
ligands which impacts the immunoreactivity as well as the
stability of the molecule and the release of iron (12). In our study,
iron sucrose was shown to be a complement activator while ferric
carboxymaltose was not. In conformity, Fell et al. demonstrated
that iron sucrose was the only formulation to induce monocyte
activation (13). We propose that low stability and high labile
iron release are major determinants for complement activation
by IV iron. Therefore, we would expect that of the iron drugs that
were not tested yet, low-molecular weight iron dextran and ferric
gluconate lead to complement activation, but not ferumoxytol
and iron isomaltoside.
The use of IV iron led to complement activation in the
majority of the patients, however, the individual response to
iron varied per patient. At present, it is not clear which
determinants affect the degree of complement activation. Based
on our findings, the role of the underlying cause of anemia
seems limited, since complement activation was seen in non-
CKD, ND-CKD, and dialysis patients. Furthermore, the rate
of infusion has been previously shown to be crucial for both,
hypersensitivity reactions and complement activation (14–16).
However, considering current infusion protocols and newer
iron formulations, the administration rate cannot explain the
complement activation by IV iron seen in this study. In addition,
the dose of iron could also affect the extent of complement
activation.We did not see a dose-dependent effect of iron sucrose
on complement (data not shown). However, our subgroups
were small and therefore our conclusions are limited. Finally,
factors such as genetic predisposition and patient characteristics,
e.g., age and sex, might also impact iron-induced complement
activation (17).
Clinically, complement activation can lead to acute and
chronic effects. Acute complement activation by IV iron could
lead to CARPA, a hypersensitivity reaction that is complement
mediated (5). In the current study no hypersensitivity reactions
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FIGURE 5 | The relative decrease in factor D correlates with the relative increase of soluble C5b-9 by intravenous iron in hemodialysis patients. (A) Plasma levels of
factor D were determined in 32 hemodialysis (HD) patients during two consecutive dialysis sessions, one with intravenous iron (Iron), and one without (No iron). During
each dialysis session, factor D levels were determined at baseline and after 4 h. Data are presented as mean and SEM. (B) The correlation between the relative
change of sC5b-9 and factor D between the two HD sessions. Correlations were evaluated using the Spearman rank correlation coefficient and paired sample t-test
was used to compare values before and after iron infusion. P < 0.05 were considered to be statistically significant (**P < 0.01).
FIGURE 6 | Myeloperoxidase correlates with the relative increase of soluble C5b-9 in the dialysis session with iron, whereas pentraxin-3 increases in both dialysis
sessions. (A) Plasma levels of myeloperoxidase (MPO) were determined in 32 hemodialysis (HD) patients during two consecutive dialysis sessions, one with
intravenous iron (Iron), and one without (No iron). During each dialysis session, MPO levels were determined at baseline and after 4 h. Data are presented as mean and
SEM. (B) The correlation between the relative change of sC5b-9 and MPO between the two HD sessions. Correlations were evaluated using the Spearman rank
correlation coefficient and paired sample t-test was used to compare values before and after iron infusion. P < 0.05 were considered to be statistically significant. (C)
Furthermore, plasma levels of pentraxin-3 (PTX3) were determined in 32 hemodialysis patients during two consecutive dialysis sessions, one with intravenous iron
(Iron), and one without (No iron). During each dialysis session, PTX3 levels were determined at baseline and after 4 h. Data are presented as mean and SEM. The
paired sample t-test was used to compare values before and after iron infusion. P-values <0.05 were considered to be statistically significant (*P < 0.05, **P < 0.01,
***P < 0.001).
occurred, which is compatible with the fact that we did not
see a 5-10-fold increase in sC5b-9, which is necessary for
the development of CARPA (16). Therefore, our studies only
function as a proof of principle that IV iron can induce
complement activation in-vivo, but do not prove nor exclude the
concept of CARPA. Moreover, chronic complement activation by
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IV Iron could contribute to prolonged/long-term oxidative stress
and inflammation as well as lead to complement consumption
thereby increasing infection risk. Although a recent study by
Macdougall et al. demonstrated the superiority of a high-
dose iron-sucrose regimen compared to a low-dose regimen,
limitations from their study design should be taken into account
(4). First, no control group without iron administration was
included, for obvious reasons. Second, regimen with other iron
formulations were not compared. As such, the safety about
long-term IV iron administration, particularly iron sucrose, is
still moot.
MPO is a protein primarily released by activated neutrophils
(18). MPO has been considered an important pathophysiological
factor in oxidative stress, contributing to the activation of
pro-atherogenic and inflammatory pathways, and to a higher
cardiovascular risk in CKD patients (19, 20). In addition, MPO
release has also been linked to iron infusion in an animal model
(21). We therefore selected MPO as a potential marker of IV
iron induced oxidative stress. Indeed, our results show that iron
administration can contribute to increased levels of MPO, most
likely through complement activation. We speculate that iron-
induced complement activation leads to neutrophil activation
resulting in the increased secretion of MPO, as shown by March
et al., and this could potentially serve as a positive feedback
loop for further complement activation (22–25). The significant
increase in MPO levels was only seen in the context of dialysis.
Possibly, the inflammatory environment caused by the dialysis
procedure primed the neutrophils, subsequently making them
more prone to complement activation-mediated oxidative stress,
as supported by earlier studies (26–28).
Previously, Malindretos et al. studied the effect of slow
infused IV iron on inflammation by measuring IL-6, CRP, and
TNF-α (29). In their study, HD itself resulted in an increase
of inflammatory parameters, while IV iron did not lead to
further increase in these markers (29). Therefore, we proceeded
to investigate iron-induced inflammation by using a different
marker, namely PTX3 which was previously shown to be a
sensitive early marker of inflammation induced by HD (30–
32). Although our results confirmed the increase of PTX3
levels during HD, there was no further increase with iron
administration, nor a correlation with complement activation.
Possibly, the inflammatory environment of HD blurs the effect
of iron on PTX3.
The strengths of our study include the use of two distinct
populations (dialysis and non-dialysis) and the size of our
groups. In the dialysis group, an important detail of our study
design is the comparison of two different dialysis sessions in
the same patient, thereby controlling for the inter-individual
response to dialysis and to iron (33, 34). In addition, the
panel of complement measurements that were involved in the
present study permitted insight in the complement pathways
that leads to iron-induced complement activation. Limitations
of our study include the use of only two available iron
preparations. Although we compared two of the most commonly
used iron formulations, not all available iron formulations were
investigated. Testing low molecular weight iron dextran would
be especially interesting since it gave the strongest complement
activation in previous in-vitro analysis. Furthermore, we did not
test different infusion rates and samples were collected only 1 h
after IV iron. Collecting samples at other time points would give
us more detailed information. Lastly, the results in the current
study are associations and therefore causality cannot be proven.
Unfortunately, there was no follow up and therefore we cannot
evaluate long-term effects of IV iron.
In conclusion, IV iron sucrose leads to complement activation
in-vivo, which partially mediates iron-induced oxidative stress.
Our findings suggests that complement activation by IV iron
in-vivo possibly occurs via AP, although a contribution of the LP
cannot be excluded. However, the mechanisms through which
iron can activate the complement system remain limited and
warrant further research. Lastly, inflammation induced by IV
iron is not related to PTX3 and therefore other inflammatory
markers should be investigated.
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